Rainer Christine

Turning precision biology into better lives.

📍 Cologne, North Rhine-Westphalia, Germany🔄 Updated September 2026💼 7 investments📅 14 years investing🗓 Last invested Jan 2021
VC🌍 Germany
7
Total investments
2
Early stage
2
Mid stage
2
Late stage
14y
Years active

Portfolio

7 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Private Investor
2021
Samplix offers a cutting-edge droplet-based instrument for single-cell analysis in immunotherapy research. Our double emulsion technology enables seamless analysis and sorting on flow cytometers. Empower your research today! Xdrop encapsulates living cells and reactive molecules in highly stable double-emulsion droplets that act as microenvironments for rapid cell–cell and cell–molecule interactions during incubation. The droplets are suitable for flow cytometry and sorting. Xdrop Sort can both generate and sort double-emulsion droplets in a user-friendly workflow that does not require any experience with fluorescence-based cell sorters. The limited volume forces fast interactions and causes secreted substances to quickly build up to detectable levels, meaning shorter screening times. The separation of the cell population into droplets containing single cells with no crosstalk means you get highly accurate, single-cell resolution results of the heterogeneous activity or potency of the cells rather than an averaged readout that hides critical information. Xdrop and Xdrop Sort are ideal for engineered cell therapy research, protein engineering and other synthetic biology workflows, and other cell interaction- or cell secretion-based workflow.
Private Investor
2021
At Biofidelity, we’re working toward a future where more people around the world have access to the life-changing power of genomics. Our novel molecular technologies simplify genomic analysis, so more patients have access to the information needed to ensure the best possible outcomes. Our vision doesn’t end with oncology, though. Our revolutionary technologies will pave the way for tomorrow’s yet-unknown scientific breakthroughs. We believe in the transformational power of genomics. We believe that with imagination and ingenuity, anything is possible. Most importantly, when it comes to humanity’s most complex problems, we believe in the power of simple.
Board Member
2019
We empower everyone to change their eating and lifestyle-related habits, improving their long-term health through personalised support and technology. We partner with health insurers, healthcare systems, and doctors to provide everyone with easy access to the care they need.
Board Member
2019
Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases. Noscendo’ s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.
Board Member
2019
Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
Board Member
2013
The focus of the company is the development, demonstration of clinical benefit, and early-stage commercialization of cryotherapy systems for the treatment of coronary plaque.
Board Member
2012
AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.
early stageBiotechnology
Experience · 9 entries
All (9)
Investments (7)
Founder (1)
Board (5)
2021
Private Investor
2021
Samplix offers a cutting-edge droplet-based instrument for single-cell analysis in immunotherapy research. Our double emulsion technology enables seamless analysis and sorting on flow cytometers. Empower your research today! Xdrop encapsulates living cells and reactive molecules in highly stable double-emulsion droplets that act as microenvironments for rapid cell–cell and cell–molecule interactions during incubation. The droplets are suitable for flow cytometry and sorting. Xdrop Sort can both generate and sort double-emulsion droplets in a user-friendly workflow that does not require any experience with fluorescence-based cell sorters. The limited volume forces fast interactions and causes secreted substances to quickly build up to detectable levels, meaning shorter screening times. The separation of the cell population into droplets containing single cells with no crosstalk means you get highly accurate, single-cell resolution results of the heterogeneous activity or potency of the cells rather than an averaged readout that hides critical information. Xdrop and Xdrop Sort are ideal for engineered cell therapy research, protein engineering and other synthetic biology workflows, and other cell interaction- or cell secretion-based workflow.
Private Investor
2021
At Biofidelity, we’re working toward a future where more people around the world have access to the life-changing power of genomics. Our novel molecular technologies simplify genomic analysis, so more patients have access to the information needed to ensure the best possible outcomes. Our vision doesn’t end with oncology, though. Our revolutionary technologies will pave the way for tomorrow’s yet-unknown scientific breakthroughs. We believe in the transformational power of genomics. We believe that with imagination and ingenuity, anything is possible. Most importantly, when it comes to humanity’s most complex problems, we believe in the power of simple.
2019
Board Member
2019
We empower everyone to change their eating and lifestyle-related habits, improving their long-term health through personalised support and technology. We partner with health insurers, healthcare systems, and doctors to provide everyone with easy access to the care they need.
Board Member
2019
Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases. Noscendo’ s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.
Board Member
2019
Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
Show all 9 entries ↓
Investment activity
2012–2021 · 7 investments
20121201312019320212
Recent (last 2 years)Earlier